Expedition Therapeutics
Expedition Therapeutics raises $165M Series B at $850M valuation
Quick Facts
Expedition Therapeutics: Series B Funding Round
Expedition Therapeutics has successfully raised $165M in Series B funding, reaching a valuation of $850M.
Company Overview
Developing novel therapeutics for cardiometabolic diseases
Funding Details
The Series B round was led by Foresite Capital, with participation from Casdin Capital.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2021
- Employees: 100+
- Category: Biotech
Investment
Expedition Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Foresite Capital: Verified investor in Series B
- Casdin Capital: Verified investor in Series B
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
